IRWD : Summary for Ironwood Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 2 hrs 48 mins

Ironwood Pharmaceuticals, Inc. (IRWD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.39+0.02 (+0.13%)
At close: 4:00 PM EST
People also watch:
INFIAEGRRPTPSGYPMNTA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close15.37
Open0.00
Bid7.99 x 100
Ask0.00 x
Day's Range15.12 - 15.56
52 Week Range7.35 - 16.89
Volume1,152,572
Avg. Volume1,406,990
Market Cap2.25B
Beta1.06
PE Ratio (TTM)-26.95
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Controladora Vuela Co Avcn SA CV (ADR) (VLRS) Going to Burn These Hedge Funds?
    Insider Monkeyyesterday

    Is Controladora Vuela Co Avcn SA CV (ADR) (VLRS) Going to Burn These Hedge Funds?

    Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Hedge Funds Are Buying Ironwood Pharmaceuticals, Inc. (IRWD)
    Insider Monkey7 days ago

    Hedge Funds Are Buying Ironwood Pharmaceuticals, Inc. (IRWD)

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • Ironwood (IRWD) Presents Positive Phase III Data on Zurampic
    Zacks22 days ago

    Ironwood (IRWD) Presents Positive Phase III Data on Zurampic

    Ironwood Pharmaceuticals, Inc. (IRWD) presented efficacy and safety data from two phase III extension studies on its marketed drug Zurampic (lesinurad) at the American College of Rheumatology (ACR).